Integra LifeSciences (NASDAQ:IART) Stock Gets Price Target Cut from JPMorgan Chase & Co.

Integra LifeSciences (NASDAQ:IART) had its price target dropped by equities researchers at JPMorgan Chase & Co. from $17.00 to $14.00 in a research note issued on Thursday, Benzinga reports. The firm currently has an “underweight” rating on the life sciences company’s stock. JPMorgan Chase & Co.’s price objective points to a potential upside of 16.41% from the stock’s current price.

IART has been the subject of a number of other research reports. BMO Capital Markets reduced their target price on shares of Integra LifeSciences from $18.00 to $15.00 and set a “market perform” rating for the company in a research report on Monday, October 5th. Weiss Ratings lowered shares of Integra LifeSciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 2nd. Truist Financial cut their price target on Integra LifeSciences from $19.00 to $15.00 and set a “hold” rating for the company in a research note on Wednesday, October 14th. Wells Fargo & Company set a $13.00 price target on Integra LifeSciences in a research report on Thursday. Finally, Wall Street Zen cut shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $16.57.

Integra LifeSciences Stock Up 1.6%

Shares of NASDAQ:IART traded up $0.19 during mid-day trading on Thursday, reaching $12.03. 104,728 shares of the stock were exchanged, compared to its average volume of 908,367. Integra LifeSciences has a one year low of $8.70 and a one year high of $20.49. The company has a quick ratio of 2.11, a current ratio of 3.60 and a debt-to-equity ratio of 1.75. The stock’s 50 day simple moving average is $15.56 and its 200-day simple moving average is $15.56. The company has a market cap of $935.26 million, a P/E ratio of -133.97, a P/E/G ratio of 0.71 and a beta of 1.21.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Wednesday, October 21st. The life sciences company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.03. The firm had revenue of $411.18 million for the quarter, compared to analyst estimates of $413.16 million. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%. During the same quarter in the previous year, the firm earned ($0.07) EPS. As a group, equities research analysts predict that Integra LifeSciences will post 2.39 EPS for the current year.

Institutional Trading of Integra LifeSciences

Several hedge funds and other institutional investors have recently made changes to their positions in IART. Paradigm Capital Management Inc. NY bought a new position in Integra LifeSciences in the 2nd quarter valued at approximately $61,766,000. Wellington Management Group LLP raised its stake in shares of Integra LifeSciences by 12.4% during the second quarter. Wellington Management Group LLP now owns 1,461,104 shares of the life sciences company’s stock valued at $26,241,000 after acquiring an additional 160,814 shares during the last quarter. Bank of America Corp DE increased its holdings in Integra LifeSciences by 71.4% in the first quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company’s stock valued at $13,325,000 after purchasing an additional 589,408 shares during the period. Glenmede Trust Co. NA lifted its holdings in Integra LifeSciences by 27.4% during the 1st quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company’s stock worth $9,276,000 after buying an additional 211,774 shares during the period. Finally, Bank of New York Mellon Corp acquired a new position in Integra LifeSciences during the 2nd quarter worth about $8,723,000. 84.78% of the stock is currently owned by institutional investors.

Trending Headlines about Integra LifeSciences

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Integra reported adjusted EPS of $0.59, above the $0.56 consensus estimate and up from $0.54 a year earlier. GAAP EPS improved to $0.19 from a $0.07 loss, while operating cash flow reached $96 million. Integra LifeSciences Surpasses Q3 Earnings Estimates
• Positive Sentiment: Quarterly revenue rose 2.3% to $411.2 million, supported by 3.9% growth in Specialty Surgery and 6.5% organic growth in Neurosurgery. The company maintained its full-year 2026 revenue guidance of $1.634 billion to $1.654 billion and adjusted EPS guidance of $2.30 to $2.40. Integra Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Integra completed a $2.1 billion refinancing that extends maturities, provides additional covenant flexibility and reduces near-term refinancing risk. Net leverage declined to 3.8x and net debt stood at approximately $1.5 billion. Integra’s Refinancing Merits a Closer Look
• Neutral Sentiment: The refinancing strengthens liquidity, but Integra expects interest expense to rise toward the high end of its previously disclosed 100-to-200-basis-point increase range, potentially limiting earnings upside.
• Negative Sentiment: Fourth-quarter revenue guidance of $413 million to $433 million implies a year-over-year decline of up to 5.2% and missed expectations. The outlook reflects the Cincinnati flood disruption and more cautious assumptions for Tissue Reconstruction. Integra Falls as Tissue Reconstruction Woes Add to Flooding Worries
• Negative Sentiment: Tissue Reconstruction revenue declined 2.2%, adjusted gross margin fell to 61.1% from 62.9%, and the Cincinnati facility disruption reduced quarterly revenue by approximately $7 million.
• Negative Sentiment: Truist lowered its price target from $19 to $15, while a law firm announced an investigation into potential securities-law violations, adding sentiment and litigation risk. Truist Cuts Integra Price Target

About Integra LifeSciences

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, orthopedics and wound care. Its portfolio includes medical devices, surgical instruments and regenerative tissue technologies designed to help healthcare professionals treat complex conditions and support patient recovery.

Integra’s neurosurgical products include dural repair products, cerebrospinal fluid management systems, cranial stabilization devices and specialized surgical instruments.